StockData
Nkarta, Inc. logo

Nkarta, Inc. (NKTX) stock

NKTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30
$1.25+0.04 (+3.31%)

Close on Nov 17, 2026Market cap $89.53MP/E –Yield 0.00%

Nkarta ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Nkarta's ebitda for the twelve months ending Jun 30, 2026 was -$122.65M. For fiscal 2025 it was -$112.80M. The highest annual figure on record is -$21.95M in fiscal 2019.

Annual ebitda

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$112.80M–
FY2024Dec 31, 2024-$118.99M–
FY2023Dec 31, 2023-$125.75M–
FY2022Dec 31, 2022-$116.36M–
FY2021Dec 31, 2021-$84.63M–
FY2020Dec 31, 2020-$50.71M–
FY2019Dec 31, 2019-$21.95M–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$40.43M–
Q1 FY2026Mar 31, 2026-$28.58M–
Q4 FY2025Dec 31, 2025-$28.66M–
Q3 FY2025Sep 30, 2025-$24.99M–
Q2 FY2025Jun 30, 2025-$24.89M–
Q1 FY2025Mar 31, 2025-$34.26M–
Q4 FY2024Dec 31, 2024-$28.62M–
Q3 FY2024Sep 30, 2024-$31.39M–
Q2 FY2024Jun 30, 2024-$28.42M–
Q1 FY2024Mar 31, 2024-$30.46M–
Q4 FY2023Dec 31, 2023-$28.89M–
Q3 FY2023Sep 30, 2023-$27.29M–
Q2 FY2023Jun 30, 2023-$36.06M–
Q1 FY2023Mar 31, 2023-$33.51M–
Q4 FY2022Dec 31, 2022-$34.28M–
Q3 FY2022Sep 30, 2022-$29.56M–
Q2 FY2022Jun 30, 2022-$27.01M–
Q1 FY2022Mar 31, 2022-$25.50M–
Q4 FY2021Dec 31, 2021-$22.29M–
Q3 FY2021Sep 30, 2021-$21.93M–
Q2 FY2021Jun 30, 2021-$21.23M–
Q1 FY2021Mar 31, 2021-$19.18M–
Q4 FY2020Dec 31, 2020-$17.70M–
Q3 FY2020Sep 30, 2020-$13.55M–
Q2 FY2020Jun 30, 2020-$10.26M–
Q1 FY2020Mar 31, 2020-$9.31M–
Q4 FY2019Dec 31, 2019-$8.55M–
Q3 FY2019Sep 30, 2019-$5.81M–
Q2 FY2019Jun 30, 2019-$4.57M–

More Nkarta figures

See a number that looks wrong?